These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18928657)

  • 21. Is the easier way ever the better way?
    Chi DS; Bristow RE; Armstrong DK; Karlan BY
    J Clin Oncol; 2011 Nov; 29(31):4073-5. PubMed ID: 21931018
    [No Abstract]   [Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer.
    Naito Y; Miura Y; Takano T
    N Engl J Med; 2010 Dec; 363(24):2371; author reply 2372. PubMed ID: 21142546
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
    Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
    Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
    Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
    Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer.
    Pectasides D; Farmakis D; Koumarianou A
    Oncology; 2005; 68(1):64-70. PubMed ID: 15809522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mathematical analysis and simulations involving chemotherapy and surgery on large human tumours under a suitable cell-kill functional response.
    Rodrigues DS; de Arruda Mancera PF
    Math Biosci Eng; 2013 Feb; 10(1):221-34. PubMed ID: 23311370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy for the management of ovarian cancer.
    Schwartz PE
    Best Pract Res Clin Obstet Gynaecol; 2002 Aug; 16(4):585-96. PubMed ID: 12413936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type of oncology specialist and treatment-related outcomes in ovarian cancer.
    Hoffman MA; Iqbal U
    J Clin Oncol; 2007 Aug; 25(23):3553; author reply 3557-8. PubMed ID: 17687165
    [No Abstract]   [Full Text] [Related]  

  • 32. The Evolving Arena of Ovarian Cancer Maintenance Therapy.
    Markman M
    Oncology; 2019; 97(4):202-205. PubMed ID: 31288226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.
    van Meurs HS; Tajik P; Hof MH; Vergote I; Kenter GG; Mol BW; Buist MR; Bossuyt PM
    Eur J Cancer; 2013 Oct; 49(15):3191-201. PubMed ID: 23850170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
    Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
    Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological response of ovarian cancer to neoadjuvant chemotherapy.
    Ivantsov AO
    Chin Clin Oncol; 2018 Dec; 7(6):59. PubMed ID: 30509080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian cancer and the battle of the specialists.
    McGuire WP
    J Clin Oncol; 2007 Aug; 25(23):3554-5; author reply 3557-8. PubMed ID: 17687166
    [No Abstract]   [Full Text] [Related]  

  • 38. CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
    Carey LA
    Clin Cancer Res; 2015 Sep; 21(18):4027-9. PubMed ID: 26374072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Lee IH; Kim YJ; Chung YS; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    PLoS One; 2018; 13(9):e0203366. PubMed ID: 30188915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy for ovarian cancer.
    Vergote I; van Gorp T; Amant F; Neven P; Berteloot P
    Oncology (Williston Park); 2005 Nov; 19(12):1615-22; discussion 1623-30. PubMed ID: 16396153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.